1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Dermatological Drugs Market Forecast 2015-2025: Opportunities for Leading Companies

Report Details
Dermatological drugs - new study showing you trends, partnerships, and predicted revenues
Where is the market for dermatological drugs heading? What are the commercial prospects for this market? Visiongain’s new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.

Our 310 page report provides 220 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket, regional and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces), company profiles and commercial developments. Read the full transcript of an exclusive expert opinion interview from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales:
- Kathleen Deardorff, Chief Operating Officer (COO) at Photocure ASA

You will find prospects for key submarkets
In addition to analyses of the overall world market, you will see revenue forecasting of five world-level submarkets to 2025:
- Skin infection drugs market forecast 2015-2025
- Dermatitis drugs market forecast 2015-2025
- Acne drugs market forecast 2015-2025
- Psoriasis drugs market forecast 2015-2025
- Other dermatological drugs market forecast 2015-2025

See revenue forecasts for products
How will leading drugs perform to 2025 at world level? Our study forecasts sales of 24 products, including these brands:
- Remicade
- Humira
- Claravis
- Epiduo
- Bepanthen
- Solodyn
- Enbrel
- Protopic
- Cubicin
- Canesten
Discover how high revenues can go. You will see what’s happening, understanding trends, challenges and opportunities.

What are the prospects for the leading regions and countries?
Our analyses show sustained growth in the dermatological drugs market, particularly in the emerging economies where growing affluence and rising government support will impact the growth of dermatological drugs.

In addition to analyses of the overall world market, you discover individual revenue forecasts for national and regional markets to 2025. Future trends within each region are examined. You will discover individual revenue forecasts for 12 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries.
- US
- China
- Japan
- Germany
- India
- France
- UK
- Italy
- Spain
- Brazil
- Russia
- Mexico
- Rest of the World

Our analyses show that emerging economies, particularly in South America and Asia, will continue to achieve high revenue growth to 2025. Various economic, geographical, and regulatory factors globally will influence the market.

Leading companies and potential for market growth
Over the last few years, the market for dermatological drugs globally has witnessed a number of strategic acquisitions and restructuring. The global dermatological drugs market will reach $24.5bn in 2015, according to visiongain’s forecast. Rising demand for dermatological drugs, expanding healthcare coverage, the success of biological drugs, and antibacterial drug resistance will aid in the growth of the overall market to 2025.

Our work shows you what organisations hold greatest potential. See profiles of 6 leading companies, including these:
- AbbVie
- Galderma
- GlaxoSmithKline
- Johnson

Table Of Contents

Dermatological Drugs Market Forecast 2015-2025: Opportunities for Leading Companies
Table of Contents
1. Report Overview
1.1 Global Dermatological Drugs: Market Overview
1.2 Global Dermatological Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction To Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction To Dermatology
2.2.1 The Structural Lay-out Of The Skin, Hair, And Nails
2.2.2 Hair And Nails
2.2.3 Sweat And Sebaceous Glands
2.2.4 Functions Of The Skin
2.3 Common Skin Diseases
2.4 Acne: The Most Common Skin Disease
2.4.1 Acne: Epidemiology
2.4.2 Acne: Causes And Pathogenesis
2.4.3 Acne: Treatment
2.5 Dermatitis: Inflammation Of The Skin
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrhoeic Dermatitis
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 Psoriasis: A Complex Multi-factorial Disease
2.7 Rosacea: Vascular Instability
2.8 Alopecia: Excessive Shedding Of Hair
2.9 Skin Infections: A Serious Healthcare Threat
2.9.1 Bacterial Skin Infections
2.9.2 Fungal Skin Infections
2.9.3 Viral Skin Infections
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents
2.11 Phases Of Clinical Trials
2.12 Dermatological Drugs: Market Definition In This Report
3. The Global Dermatological Drugs Market, 2015-2025
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation Of The Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market In 2014
3.4 The Global Dermatological Drugs Market: Market Forecast 2015-2025
3.5 Dermatological Drugs: Changing Market Shares By Sector 2015-2025
4. The Psoriasis Drugs Market: Market Analysis And Forecast 2015-2025
4.1 Psoriasis Treatments: The Dominance Of Biologics
4.1.1 Leading Products In The Psoriasis Drugs Market, 2014
4.2 Psoriasis: Market Trends And Developments, 2015
4.2.1 Biological Drugs In Psoriasis Treatment: A Brief Overview
4.2.2 Issues Around Patent Protection, The Threat Of Biosimilars And Pricing
4.2.3 The Disadvantages Of Biologics In Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2015-2025
4.3.1 Psoriasis Drugs: Changing Market Shares By Leading Drugs 2015-2025
4.4 Leading Drugs Used In The Treatment Of Psoriasis
4.5 Humira (adalimumab) - AbbVie
4.5.1 Humira: Historical Sales Analysis, 2010-2014
4.5.2 Humira: Sales Forecast 2015-2025
4.5.3 Future Prospects For Biosimilar Versions Of Humira
4.6 Stelara (ustekinumab) - Johnson and Johnson
4.6.1 Stelara: Historical Sales Analysis, 2010-2014
4.6.2 Stelara: Sales Forecast 2015-2025
4.6.3 Intensifying Competition For Stelara
4.7 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda
4.7.1 Enbrel: Co-Promotions And Marketing Rights
4.7.2 Enbrel: Historical Sales Analysis, 2008-2014
4.7.3 Enbrel: Patent Expiries and Potential Competition, 2015-2025
4.7.4 Enbrel: Sales Forecast 2015-2025
4.7.5 Enbrel Auto-injector Pens: A Driver Of Growth In Recent Years
4.7.6 Competition From Other Drugs
4.7.7 Biosimilar Competition For Enbrel
4.8 Remicade (infliximab) - Johnson and Johnson
4.8.1 Remicade: Historical Sales Analysis, 2010-2014
4.8.2 Remicade: Patent Expiries and Potential Competition, 2015-2025
4.8.3 Remicade: Sales Forecast 2015-2025
4.9 Daivobet (betamethasone/calcipotriene) - LEO Pharma
4.9.1 Daivobet: Sales Forecast 2015-2025
4.9.2 LEO Pharma's Life Cycle Management Of Daivobet
4.9.3 Daivobet/Dovobet/Taclonex - Generic Competition
4.10 Soriatane (acitretin) - GlaxoSmithKline
4.10.1 Soriatane: Sales Forecast 2015-2025
4.11 Other Psoriasis Drugs
4.11.1 Cimzia (certolizumab) - UCB
4.11.2 Cosentyx (secukinumab) - Novartis
4.11.3 Otezla (apremilast) - Celgene
4.11.4 Sorilux (calcipotriene foam) - GSK
4.11.5 Other Psoriasis Drugs: Sales Forecast 2015-2025
4.12 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis And Forecast 2015-2025
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products In The Skin Infection Drugs Market, 2014
5.2 Skin Infection Drugs: Market Forecast 2015-2025
5.2.1 Skin Infection Drugs: Changing Market Shares By Leading Drugs 2015-2025
5.3 Leading Drugs Used In The Treatment Of Skin Infections
5.4 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck and Co
5.4.1 Acquisition By Merck and Co
5.4.2 Generic Competition For Cubicin
5.4.3 Cubicin: Sales Forecast 2015-2025
5.4.4 Lifecycle Management Strategies For Cubicin
5.5 Zyvox (linezolid) - Pfizer
5.5.1 Zyvox: Historical Sales Analysis, 2010-2014
5.5.2 Zyvox: Sales Forecast 2015-2025
5.5.3 The Threats To Zyvox Sales From Competing New Drugs
5.6 Valtrex (valaciclovir) - GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2014
5.6.2 Valtrex: Sales Forecast 2015-2025
5.7 Canesten (clotrimazole) - Bayer
5.7.1 Canesten: Historical Sales Analysis, 2011-2014
5.7.2 Canesten: Sales Forecast 2015-2025
5.8 Lamisil (terbinafine) - Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2015-2025
5.9 Bactroban (mupirocin) - GSK
5.9.1 Bactroban: Historical Sales Analysis, 2010-2013
5.9.2 Bactroban: Sales Forecast 2015-2025
5.10 Other Skin Infection Drugs
5.10.1 Dalvance (dalbavancin) - Durata Therapeutics
5.10.2 Jublia (efinaconazole) - Valeant
5.10.3 Kerydin (tavaborole) - Anacor
5.10.4 Sivextro (tedizolid) - Cubist Pharmaceuticals
5.10.5 Zovirax (acyclovir) - Valeant/GSK
5.10.5.1 Valeant Acquires Zovirax In US And Canada
5.10.5.2 Mylan's Generic Zovirax And Actavis' Authorised Generic
5.10.6 Other Skin Infection Drugs: Sales Forecast 2015-2025
5.11 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis And Forecast 2015-2025
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products In The Acne Drugs Market, 2014
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise Of Combination Therapies In Acne Treatment
6.2.2 Oral Contraceptives In Treating Acne
6.2.3 The Threat Of Generic Competition In The Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2015-2025
6.3.1 Acne Drugs: Changing Market Shares By Leading Drugs 2015-2025
6.4 Leading Drugs In The Acne Drugs Market
6.5 Solodyn (minocycline) - Valeant
6.5.1 Solodyn: Sales Forecast 2015-2025
6.5.2 Antitrust Action Over Solodyn Pay-For-Delay Deals
6.5.3 Impax And Medicis Collaborating On Advanced Solodyn
6.5.4 Medicis And Lupin Settle
6.6 Epiduo (adapalene/benzoyl peroxide) - Galderma/ Nestle Skin Health
6.6.1 Epiduo: Sales Forecast 2015-2025
6.6.2 Galderma Settlement Agreement Over Generic Epiduo
6.6.3 Paediatric Approval For Epiduo
6.7 Claravis (isotretinoin) - Teva
6.7.1 Claravis: Sales Forecast 2015-2025
6.8 Aczone (dapsone) - Allergan
6.8.1 Aczone: Sales Forecast 2015-2025
6.9 Differin (adapalene) - Galderma/ Nestle Skin Health
6.9.1 Recent Generic Competition To Differin
6.9.2 Differin: Sales Forecast 2015-2025
6.9.3 Federal Circuit Court Invalidates Differin Patents
6.10 Absorica/Epuris (CIP-isotretinoin) - Cipher/ Sun Pharma
6.10.1 Absorica/Epuris: Sales Forecast 2015-2025
6.11 Ziana (clindamycin/tretinoin) - Valeant Pharmaceuticals International
6.11.1 Valeant's Patent Settlement With Actavis Over Ziana
6.11.2 Ziana: Sales Forecast 2015-2025
6.12 Doryx (doxycycline) - Actavis/ Mayne Pharma
6.12.1 Lifecycle Management Strategies For Doryx
6.12.2 Divestment Agreement With Mayne Pharma
6.12.3 Generic Competition For Doryx
6.12.4 Doryx: Sales Forecast 2015-2025
6.13 Other Acne Drugs
6.13.1 Acanya (clindamycin/benzoyl peroxide) - Dow / Valeant
6.13.1.1 Acanya: Financial Analysis
6.13.1.2 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
6.13.1.3 Legal Battles Involving Dow/Valeant, Perrigo, And Watson
6.13.2 Amnesteem (isotretinoin) - Mylan
6.13.2.1 Amnesteem: Financial Analysis
6.13.3 Diane (cyproterone/ethinyl estradiol) - Bayer
6.13.4 Duac (clindamycin/benzoyl peroxide) - GlaxoSmithKline
6.13.4.1 Duac: Financial Analysis
6.13.5 Veltin (tretinoin/clindamycin) - GSK
6.13.6 Other Acne Drugs: Sales Forecast 2015-2025
6.14 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis And Forecast 2015-2025
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products In The Dermatitis Drugs Market, 2014
7.2 Dermatitis Drugs: Market Forecast 2015-2025
7.2.1 Dermatitis Drugs: Changing Market Shares By Leading Drugs 2015-2025
7.3 Leading Drugs In The Dermatitis Drugs Market
7.4 Bepanthen (dexpanthenol)/ Bepanthol - Bayer
7.4.1 Bepanthen: Sales Forecast 2015-2025
7.5 Protopic (tacrolimus) - Astellas Pharma/ Roche
7.5.1 Protopic Benefits From Expanded Indication
7.5.2 Generic Competition For Protopic
7.5.3 Protopic: Sales Forecast 2015-2025
7.6 Elidel (pimecrolimus) - Meda Pharma/ Valeant
7.6.1 Elidel: Sales Forecast 2015-2025
7.7 Elocon (mometasone) - Merck and Co
7.7.1 Elocon: Sales Forecast 2015-2025
7.8 Other Dermatitis Drugs: Sales Forecast 2015-2025
7.9 Dermatitis Drugs: Market Outlook
8. Leading National Markets For Dermatological Drugs, 2015-2025
8.1 The Dermatological Drugs Market By Region
8.1.1 The Global Distribution Of Dermatological Drugs In 2014
8.2 Leading National Markets: Forecast 2015-2025
8.2.1 Changing Market Shares By Region, 2015-2025
8.3 Regional Dermatological Drugs Markets: Analysis And Forecasts, 2015-2025
8.4 United States: The Largest Dermatological Drugs Market
8.4.1 The Impact Of An Expanding Medicare Coverage
8.4.2 Legislative Environment Stimulating Biosimilars Market?
8.4.3 US Dermatological Drugs Market: Market Forecast 2015-2025
8.5 The EU5 Markets: Growth Expected In Each Country
8.5.1 EU5 Dermatological Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
8.5.2 Germany
8.5.2.1 German Dermatological Drugs Market: Market Forecast 2015-2025
8.5.3 France
8.5.3.1 French Dermatological Drugs Market Forecast 2015-2025
8.5.4 UK
8.5.4.1 UK Dermatological Drugs Market Forecast 2015-2025
8.5.5 Italy
8.5.5.1 Italian Dermatological Drugs Market Forecast 2015-2025
8.5.6 Spain
8.5.6.1 Spanish Dermatological Drugs Market Forecast 2015-2025
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Dermatological Drugs Market Forecast 2015-2025
8.7 China
8.7.1 Expansion Of Healthcare Coverage And Reimbursement In China
8.7.2 Improving Public Perception Of Dermatology In China
8.7.3 Price Controls And The Anhui Model
8.7.4 Chinese Dermatological Drugs Market Forecast 2015-2025
8.8 India
8.8.1 The Effects Of The Drug Prices Control Order Of 2013
8.8.2 India's Expansion Of Healthcare Provision
8.8.3 Indian Dermatological Drugs Market Forecast 2015-2025
8.9 Brazil
8.9.1 The Growth In Brazil's Healthcare Landscape
8.9.2 Clearer Access To Medicines In Brazil
8.9.3 Brazilian Dermatological Drugs Market Forecast 2015-2025
8.10 Russia
8.10.1 Pharma2020 Strategy - Healthcare And Industry Reform
8.10.2 Russian Dermatological Drugs Market Forecast 2015-2025
8.11 Mexico
8.11.1 Seguro Popular: Mexican Healthcare Reform
8.11.2 Are Multinationals Waking Up To Mexico's Potential?
8.11.3 Mexican Dermatological Drugs Market Forecast 2015-2025
8.12 Rest of the World
8.12.1 The Rest of the World Dermatological Drugs Market Forecast 2015-2025
9. Leading Companies In The Dermatological Drugs Market, 2015-2025
9.1 Dermatological Drugs - A Rapidly Consolidating Market
9.2 Galderma (Nestle Skin Health S.A.)
9.2.1 Galderma: Dermatological Drugs Portfolio, 2015
9.2.2 Galderma: Recent Developments
9.2.2.1 Nestle's Acquisition Of Galderma
9.2.2.2 Approval Of Soolantra For Rosacea
9.2.2.3 Mirvaso Launched For Rosacea
9.3 Johnson and Johnson
9.3.1 Johnson and Johnson: Dermatological Drugs Portfolio, 2015
9.3.2 Johnson and Johnson Dermatological Drugs Sales Forecast 2015-2025
9.3.3 Johnson And Johnson: Dermatological Drug Development Efforts, 2015
9.4 AbbVie
9.4.1 AbbVie: Dermatological Drugs Portfolio, 2015
9.4.2 AbbVie Dermatological Drugs Sales Forecast 2015-2025
9.4.3 AbbVie: Dermatological Drugs Development Pipeline, 2015
9.4.3.1 BT-061 (tregalizumab) For The Treatment Of Psoriasis
9.5 GlaxoSmithKline (GSK)
9.5.1 GSK: Dermatological Drugs Portfolio, 2015
9.5.2 GlaxoSmithKline (GSK) Dermatological Drugs Sales Forecast 2015-2025
9.5.3 GlaxoSmithKline (GSK): Recent Developments
9.5.3.1 Business Restructuring Arrangements With Novartis
9.5.3.2 Tafinlar and Mekinist Combination Approved by FDA, Withdrawn in EU
9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2015
9.6 Pfizer
9.6.1 Pfizer: Dermatological Drugs Portfolio, 2015
9.6.2 Pfizer Dermatological Drugs Sales Forecast 2015-2025
9.6.3 Pfizer: Dermatological Drugs Development Pipeline, 2015
9.7 LEO Pharma
9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2015
9.7.2 LEO Pharma Dermatological Drugs Sales Forecast 2015-2025
10. Dermatological Drugs: Research And Development Pipeline, 2015-2025
10.1 Innovative Products Currently In Development Will Drive Growth
10.1.1 New Technology In RandD Pipeline Activities
10.1.1.1 Reformulation
10.1.1.2 Combination Treatments
10.1.1.3 New Mechanisms And Drug Delivery Technologies
10.1.1.4 Potential Market Entrants
10.2 Psoriasis Drugs Development Pipeline, 2015
10.2.1 Psoriasis Drugs In Phase 3 Development
10.2.1.1 000-0551 Lotion (halobetasol) - Therapeutics, Inc
10.2.1.2 AMG 827 (brodalumab) - AstraZeneca/ Amgen
10.2.1.3 CF101 (IB-MECA) - Can-Fite BioPharma
10.2.1.4 CNTO 1959 (guselkumab) - MorphoSys/ Janssen
10.2.1.5 LAS41008 (dimethyl fumarate) - Almirall
10.2.1.6 LEO 90100 - LEO Pharma
10.2.1.7 LY2439821 (ixekizumab) - Eli Lilly
10.2.1.8 MK-3222/SCH 900222 (tildrakizumab) - Merck
10.2.1.9 STF 115469 (calcipotriene foam) - GSK
10.2.1.10 Xeljanz (tofacitinib) - Pfizer
10.2.2 Psoriasis Drugs In Phase 2 Development
10.2.2.1 AN2728 (PDE-4 inhibitor) - Anacor Pharmaceuticals
10.2.2.2 CT327 (TrkA inhibitor) - Creabilis Therapeutics
10.2.2.3 ASP015K (JAK inhibitor) - Astellas Pharma
10.2.2.4 Jakavi/Jakafi (ruxolitinib) - Incyte/ Novartis
10.2.2.5 LY3009104 (baricitinib) - Incyte/ Eli Lilly
10.2.2.6 PH-10 (Rose Bengal) - Provectus Biopharmaceuticals
10.2.3 Psoriasis Drugs In Phase 1 And Pre-clinical Development
10.3 Skin Infection Drugs Development Pipeline, 2015
10.3.1 Drugs In Phase 3 Development For Skin Infections
10.3.1.1 Delafloxacin (delafloxacin) - Melinta Pharmaceuticals
10.3.1.2 NB-001 - NanoBio Corporation
10.3.1.3 Orbactiv/ Nuvocid (oritavancin) - The Medicines Company
10.3.1.4 Luliconazole - Topica Pharmaceuticals
10.3.2 Drugs In Phase 2 Development For Skin Infections
10.3.3 Drugs In Phase 1 And Preclinical Pipeline For Skin Infections
10.4 Acne Drugs Development Pipeline, 2015
10.4.1 Drugs In Phase 3 Development For Acne
10.4.1.1 Duac low dose (clindamycin/ benzoyl peroxide) - GlaxoSmithKline
10.4.1.2 Visonac (photodynamic therapy) - Photocure
10.4.2 Drugs In Phase 2 Development For Acne
10.4.3 Drugs In Phase 1 And Pre-clinical Development For Acne
10.4.4 A Possible Vaccine For Acne
10.5 Dermatitis Drugs Development Pipeline, 2015
10.5.1 Drugs In Phase 3 Development For Dermatitis
10.5.1.1 Toctino (alitretinoin) - GSK
10.5.1.2 Dermadexin and Pruridexin (P3CGM) - Cipher Pharmaceuticals
10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) - Pierre Fabre
10.5.1.4 REGN668/SAR231893 (dupilumab) - Regeneron/ Sanofi
10.5.1.5 Soriatane (acitretin) - InnovaDerm/Tribute Pharmaceuticals
10.5.2 Drugs In Phase 2 Development For Dermatitis
10.5.3 Drugs In Phase 1 And Preclinical Stages Of Development For Dermatitis
10.6 Other Dermatological Drugs Development Pipeline, 2015
10.6.1 Other Dermatological Drugs: Filed or Recently Launched
10.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall
10.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera
10.6.1.3 Keytruda (MK-3475, Pembrolizumab) - Merck
10.6.1.4 Mirvaso (brimonidine) - Galderma
10.6.1.5 Picato (ingenol mebutate) - LEO Pharma
10.6.1.6 Xolair (omalizumab) - Novartis/ Roche
10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2015
10.6.2.1 Atralin (tretinoin) - Valeant
10.6.2.2 BMS-936558 (nivolumab) - Bristol-Myers Squibb
10.6.2.3 CD5024 (ivermectin) - Galderma
10.6.2.4 Latisse (bimatoprost) - Allergan (Actavis)
10.6.2.5 LEE011, LGX818, and MEK162 - Novartis
10.6.2.6 Oleogel-S10 (triterpene extract) - Birken AG
10.6.2.7 PV-10 (Rose Bengal) - Provectus Pharmaceuticals
10.6.2.8 SR-T100 gel (Solanum incanum extract) - GandE Herbal Biotechnology
10.6.2.9 TVEC (talimogene laherparepvec) - Amgen
10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2015
10.6.4 Other Dermatological Drugs: Phase 1 and Preclinical Pipeline
11. Qualitative Analysis Of The Dermatological Drugs Market, 2015-2025
11.1 Market Factors Influencing Dermatological Drugs
11.2 SWOT Analysis Of The Global Dermatological Drugs Market, 2015-2025
11.2.1 Strengths
11.2.1.1 The High Unmet Clinical Need In Dermatology
11.2.1.2 A Healthy Pipeline Of Development-Stage Products
11.2.1.3 Strong Industry-Physician Relationships
11.2.2 Weaknesses
11.2.2.1 Limited Efficacy And Adverse Effects May Impact Product Uptake
11.2.2.2 Patient Adherence - A Major Challenge To Treatment Design
11.2.2.3 Impending Patent Expiries And The Challenges Posed By Generic Competition
11.2.3 Opportunities
11.2.3.1 The High-Growth Sectors In Dermatology
11.2.3.2 Personalised Dermatology: Technological Advances In Genomics
11.2.3.3 Advances In Topical Drug Delivery Methods Offers Product Differentiation
11.2.3.4 Consolidation Within Dermatology - Opportunity For Synergistic Growth?
11.2.4 Threats
11.2.4.1 Uncertain Surrounding Reimbursement And Payment Approvals
11.2.4.2 The Rising Cost Of Research And Development
11.2.4.3 Downward Pressures On Drug Prices
11.3 Porter's Five Force Analysis Of The Global Dermatological Drugs Market, 2015-2025
11.3.1 Threat Of New Entrants
11.3.2 Threat Of Substitutes
11.3.3 Rivalry Among Competitors
11.3.4 Power Of Buyers
11.3.5 Power Of Suppliers
12. Expert Opinions from Our Primary Research
12.1 Interview With Kathleen Deardorff, Chief Operating Officer At Photocure ASA
12.1.1 Visonac As An Innovative First-In-Class Treatment
12.1.2 Photocure's Development Plans For Visonac
12.1.3 Commercialisation Strategy For Visonac
12.1.4 On The Geographical Reach Of Acne Treatments
12.1.5 The Key Unmet Needs Within Patient Populations For Acne
12.1.6 The Key Forces Driving And Restraining The Development Of Acne Therapies
12.1.7 On The Current Development Pipeline For Acne Therapies
12.1.8 On Photocure's Plans For Future Growth
12.1.9 Future Prospects For The Acne Treatments Market
13. Conclusions
13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
13.2 Leading Sectors In Dermatological Drugs In 2014
13.3 Leading Regions In The Dermatological Drugs Market In 2014
13.4 Future Outlook For The Various Sectors Within The Dermatological Drugs Market, 2015-2025
13.5 What Does The Future Hold For Dermatological Drugs?

List of Tables
Table 1.1 Global Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2014-2025 (Redacted Data)
Table 2.1 Clinical Trial Phases, 2015
Table 3.1 The Global Dermatological Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2014
Table 3.2 The Global Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2014-2025
Table 3.3 The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2014-2019, 2019-2025, 2014-2025
Table 3.4 The Global Dermatological Drugs Market: Market Share (%) by Sector, 2014, 2019, 2025
Table 4.1 Top Drugs In The Psoriasis Drugs Market: Revenue ($m) and Market Shares (%), 2014
Table 4.2 Psoriasis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 4.3 The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 4.4 Humira: Historical Sales ($m, AGR%), 2010-2014
Table 4.5 Humira: AbbVie Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.6 Stelara: Historical Sales ($m, AGR%), 2010-2014
Table 4.7 Stelara: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.8 Enbrel: Historical Sales ($m,bn Yen, AGR%) by Company, 2008-2014
Table 4.9 Enbrel: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.10 Remicade: Historical Sales ($m, bn Yen, AGR%), 2010-2014
Table 4.11 Remicade: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.12 Daivobet: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.13 Soriatane: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.14 Other Psoriasis Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.1 Top Drugs In The Skin Infection Drugs Market: Revenue ($m) and Market Share (%), 2014
Table 5.2 Skin Infection Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 5.3 The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 5.4 Cubicin: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.5 Zyvox: Historical Sales ($m, AGR%), 2010-2014
Table 5.6 Zyvox: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.7 Valtrex: Historical Sales ($m, £m, AGR%), 2010-2014
Table 5.8 Valtrex: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.9 Canesten: Historical Sales ($m, Euros, AGR%), 2011-2014
Table 5.10 Canesten: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.11 Lamisil: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.12 Bactroban: Historical Sales ($m, Euros, AGR%), 2010-2013
Table 5.13 Bactroban: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 5.14 Other Skin Infection Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.1 Top Drugs In The Acne Drugs Market: Revenue ($m) and Market Share (%), 2014
Table 6.2 Acne Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 6.3 The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 6.4 Solodyn (Valeant): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.5 Epiduo (Galderma/ Nestle): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.6 Claravis (Teva): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.7 Aczone (Allergan): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.8 Differin (Galderma/ Nestle): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.9 Absorica/Epuris: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.10 Ziana: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.11 Doryx: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.12 Other Acne Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.1 Top Drugs In The Dermatitis Drugs Market: Revenue ($m) and Market Share (%), 2014
Table 7.2 Dermatitis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 7.3 The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
Table 7.4 Bepanthen/Bepanthol: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.5 Protopic: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.6 Elidel: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.7 Elocon: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.8 Other Dermatitis Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.1 The Global Dermatological Drugs Market: Market Size ($m) and Market Share (%) by Region, 2014
Table 8.2 Global Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2014-2025
Table 8.3 The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2014-2019, 2019-2025, and 2014-2025
Table 8.4 The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2014, 2019, and 2025
Table 8.5 The US Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.6 US Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.7 The EU5 Dermatological Drugs Market: Revenue ($m), and Market Share (%) by Country, 2014
Table 8.8 The EU5 Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.9 The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2014, 2019, 2025
Table 8.10 The German Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.11 The German Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.12 The French Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.13 The French Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.14 The UK Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.15 The UK Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.16 The Italian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.17 The Italian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.18 The Spanish Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.19 The Spanish Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.20 The Japanese Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.21 The Japanese Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.22 The Chinese Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.23 The Chinese Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.24 The Indian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.25 The Indian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.26 The Brazilian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.27 The Brazilian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.28 The Russian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.29 The Russian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.30 The Mexican Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.31 The Mexican Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.32 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2025
Table 8.33 The Rest of the World Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.1 Galderma: Company Overview, 2013 And 2014
Table 9.2 Johnson and Johnson: Company Overview, 2014
Table 9.3 Johnson and Johnson: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.4 AbbVie: Company Overview, 2014
Table 9.5 AbbVie: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.6 GlaxoSmithKline: Company Overview, 2014
Table 9.7 GlaxoSmithKline: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.8 GlaxoSmithKline: Dermatological Drugs Pipeline, 2015
Table 9.9 Pfizer: Company Overview, 2014
Table 9.10 Pfizer: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.11 LEO Pharma: Company Overview, 2014
Table 9.12 LEO Pharma: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 10.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.3 Psoriasis Drugs Pipeline: Phase 1 and Pre-Clinical Drugs, 2015
Table 10.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.6 Acne Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.7 Acne Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2015
Table 10.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2015
Table 10.12 Other Dermatological Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.13 Other Dermatological Drugs Pipeline: Phase 1 and Preclinical Drugs, 2015
Table 11.1 SWOT Analysis of the Global Dermatological Drugs Market, 2015-2025
Table 13.1 Global Dermatological Drugs: Market Forecast ($m, CAGR%), 2014, 2018, 2021, 2025
Table 13.2 The Global Dermatological Drugs Market: Market Size ($m) and Market Shares (%) by Sector, 2014
Table 13.3 The Global Dermatological Drugs Market: Market Forecast ($m) by Region, 2014, 2018, 2021, 2025
Table 13.4 The Global Dermatological Drugs Market: Market Forecast ($m) by Sector, 2014, 2018, 2021, 2025

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Selenium Sulfide Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Selenium Sulfide Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Selenium sulfide is sulfide salt of selenium. It is present in bright orange or yellow-orange powder or tablet form at room temperature. It is insoluble in water or ether. It can be dissolved in carbon ...

Dermatology Devices Market by Diagnostic Device (Imaging Device, Dermatoscope, Microscope), Treatment Device (Electrosurgical, Cryotherapy, Laser), Application (Skin Cancer Diagnosis, Acne, Psoriasis, Skin Rejuvenation, Warts) - Global Forecasts to 2021

Dermatology Devices Market by Diagnostic Device (Imaging Device, Dermatoscope, Microscope), Treatment Device (Electrosurgical, Cryotherapy, Laser), Application (Skin Cancer Diagnosis, Acne, Psoriasis, Skin Rejuvenation, Warts) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The dermatology devices market is expected to reach USD 14.17 billion by 2021 from USD 8.22 billion in 2016, at a CAGR of 11.50%. The global dermatology devices market is segmented based on diagnostic ...

Global Advanced Wound Care Industry

Global Advanced Wound Care Industry

  • $ 4950
  • Industry report
  • September 2016
  • by Global Industry Analysts

This report analyzes the worldwide markets for Advanced Wound Care in US$ Thousand by the following Product Segments: Dressings (Alginate Dressings, Hydrocolloids, Hydrogels, Foam Dressings, Film Dressings, ...

Global Food Hydrocolloids Market

October 2016 $ 4250

Download Unlimited Documents from Trusted Public Sources

Dermatological Treatment Market in India

  • August 2016
    2 pages
  • Dermatological ...  

  • India  

View report >

Dermatological Treatment Market in the UK

  • July 2016
    7 pages
  • Dermatological ...  

    Dermatological ...  

    Ophthalmology  

  • United Kingdom  

    Europe  

View report >

Dermatological Treatment Market in Canada

  • June 2016
    40 pages
  • Dermatological ...  

    Vaccine  

    Influenza  

  • Canada  

View report >

Related Market Segments :

Dermatological Treatment

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.